The aim of the study is to determine whether switching from an antiretroviral regimen
containing abacavir and/or didanosine to one containing maraviroc will lead to a reduction in
platelet reactivity and inflammatory markers at weeks 12 and 24 thereby conferring a
reduction in cardiac risk.
In addition the study will assess the efficacy of a maraviroc containing regimen in
combination with a boosted protease inhibitor in terms of tolerability and achieving long
term viral suppression as assessed at week 48.
The investigators hypothesize that there will be a rapid reduction in platelet reactivity on
switching to maraviroc and that a boosted protease inhibitor in combination with maraviroc
will provide a safe and efficacious antiretroviral regimen enabling a reduction in cardiac
risk whilst maintaining virological suppression.